Visceral Hyperalgesia: When to Consider Gabapentin Use in Neonates-Case Study and Review

Joseph Asaro, Christine A Robinson, Philip T Levy, Joseph Asaro, Christine A Robinson, Philip T Levy

Abstract

Visceral hyperalgesia refers to increased pain sensation in response to gastrointestinal sensory stimulus. In neonates with neurological impairments, gabapentin has been successfully used as a treatment for visceral hyperalgesia in neonates. The authors describe a preterm infant with myelomeningocele and persistent neuropathic pain that manifested as irritability, hypertonicity, poor weight gain, and feeding intolerance. After exclusion of other etiologies, the diagnosis of visceral hyperalgesia was suspected and the infant was treated with gabapentin. Following appropriate titration to effect and close monitoring of side effects of gabapentin, he subsequently demonstrated improved tone, decreased irritability with feedings, and appropriate weight gain. In addition, the authors provide a review of the available literature of gabapentin use in neonates and offer suggestions on when to consider starting gabapentin in a neonate with neurological impairment and chronic unexplained gastrointestinal manifestations.

Keywords: gabapentin; neonates; neuropathic pain; visceral hyperalgesia.

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Hauer JM, Wical BS, Charnas L. Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment. Pediatrics. 2007;119(2):e519–e522.
    1. Hauer J, Mackey D. Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. J Palliat Med. 2013;16(4):455–458.
    1. Edwards L, DeMeo S, Hornik CD, et al. Gabapentin use in the neonatal intensive care unit. J Pediatr. 2015;169:310–312.
    1. Haney AL, Garner SS, Cox TH. Gabapentin therapy for pain and irritability in a neurologically impaired infant. Pharmacotherapy. 2009;29(8):997–1001.
    1. Brzenski A, Greenberg M. Use of gabapentin as an adjunct agent in the treatment of neonatal abstinence syndrome: a case report. Int J Med Pharm Case Reports. 2015;3(4):84–88.
    1. Behm MO, Kearns GL. Treatment of pain with gabapentin in a neonate. Pediatrics. 2001;108(2):482–484.
    1. Schwantes S, O’Brien HW. Pediatric palliative care for children with complex chronic medical conditions. Pediatr Clin North Am. 2014;61(4):797–782.
    1. Haig GM, Bockbrader HN, Wesche DL, et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol. 2001;41(5):507–514.
    1. Ouellet D. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res. 2001;47(3):229–241.
    1. Morris GL. Gabapentin. Epilepsia. 1999;40(suppl 5):S63–S70.
    1. Norton JW. Gabapentin withdrawal syndrome. Clin Neuropharmacol. 2001;24(4):245–246.
    1. Schwantes S. Effectiveness of gabapentin on chronic irritability in neurologically impaired children. In: [Internet]. Bethesda, MD: National Library of Medicine (US) . Published 2012. Updated February 8, 2016. Accessed December 1, 2016.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다